应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
KYTX Kyverna Therapeutics
盘后交易 04-28 17:15:25 EDT
8.70
-0.29
-3.23%
盘后
8.87
+0.17
+1.95%
17:10 EDT
最高
9.23
最低
8.58
成交量
86.55万
今开
8.96
昨收
8.99
日振幅
7.23%
总市值
5.26亿
流通市值
2.90亿
总股本
6,044万
成交额
760.17万
换手率
2.60%
流通股本
3,330万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
Kyverna Therapeutics股价大涨7.3% 罕见肌肉疾病细胞疗法中期数据表现强劲
美股速递 · 04-22
Kyverna Therapeutics股价大涨7.3% 罕见肌肉疾病细胞疗法中期数据表现强劲
Kyverna Therapeutics股价盘前飙升21% 中期试验显示其疗法改善僵人综合征患者活动能力
美股速递 · 04-22
Kyverna Therapeutics股价盘前飙升21% 中期试验显示其疗法改善僵人综合征患者活动能力
Kyverna Therapeutics公布KYSA-8试验主要分析结果：Miv-Cel治疗SPS取得积极成效
美股速递 · 04-22
Kyverna Therapeutics公布KYSA-8试验主要分析结果：Miv-Cel治疗SPS取得积极成效
Kyverna Therapeutics公布Miv-Cel治疗全身型重症肌无力二期长期积极数据
美股速递 · 04-20
Kyverna Therapeutics公布Miv-Cel治疗全身型重症肌无力二期长期积极数据
Kyverna Therapeutics：24周时100%患者实现MG-ADL与QMG快速持续改善
美股速递 · 04-20
Kyverna Therapeutics：24周时100%患者实现MG-ADL与QMG快速持续改善
Kyverna Therapeutics与Jefferies签订公开市场销售协议 日期为2025年3月27日——SEC文件披露
美股速递 · 04-03
Kyverna Therapeutics与Jefferies签订公开市场销售协议 日期为2025年3月27日——SEC文件披露
Kyverna Therapeutics发布业务进展及2025年第四季度与全年财务业绩
美股速递 · 03-27
Kyverna Therapeutics发布业务进展及2025年第四季度与全年财务业绩
Kyverna Therapeutics, Inc.盘中异动 快速跳水5.29%
市场透视 · 03-03
Kyverna Therapeutics, Inc.盘中异动 快速跳水5.29%
Kyverna Therapeutics, Inc.盘中异动 股价大跌5.06%
市场透视 · 01-28
Kyverna Therapeutics, Inc.盘中异动 股价大跌5.06%
Kyverna Therapeutics, Inc.盘中异动 下午盘快速跳水5.06%报8.26美元
市场透视 · 01-09
Kyverna Therapeutics, Inc.盘中异动 下午盘快速跳水5.06%报8.26美元
新闻稿：Kyverna Therapeutics宣布拟进行普通股的公开发行
投资观察 · 2025-12-16
新闻稿：Kyverna Therapeutics宣布拟进行普通股的公开发行
Kyverna Therapeutics公布Miv-Cel (Kyv-101)在僵人综合征注册Kysa-8试验中的积极关键数据
美股速递 · 2025-12-15
Kyverna Therapeutics公布Miv-Cel (Kyv-101)在僵人综合征注册Kysa-8试验中的积极关键数据
Kyverna Therapeutics将发布Kyv-101在僵人综合症注册性第二阶段Kysa-8试验的顶线结果
美股速递 · 2025-12-15
Kyverna Therapeutics将发布Kyv-101在僵人综合症注册性第二阶段Kysa-8试验的顶线结果
Caribou Biosciences报告了关于同种异体CAR T疗法的临床数据，而Kyverna Therapeutics则推进了自身免疫项目Caribou Biosciences Reports Clinical Data on Allogeneic CAR T Therapies While Kyverna Therapeutics Advances Autoimmune Program
动脉网 · 2025-11-05
Caribou Biosciences报告了关于同种异体CAR T疗法的临床数据，而Kyverna Therapeutics则推进了自身免疫项目Caribou Biosciences Reports Clinical Data on Allogeneic CAR T Therapies While Kyverna Therapeutics Advances Autoimmune Program
Kyverna Therapeutics公司预计现金流可持续至2027年，支持其SPS的BLA申请及Mg三期临床试验
美股速递 · 2025-11-03
Kyverna Therapeutics公司预计现金流可持续至2027年，支持其SPS的BLA申请及Mg三期临床试验
Kyverna Therapeutics公布Kysa-6研究中Kyv-101在广泛性重症肌无力治疗中的积极一期2临床数据
美股速递 · 2025-10-29
Kyverna Therapeutics公布Kysa-6研究中Kyv-101在广泛性重症肌无力治疗中的积极一期2临床数据
Kyverna Therapeutics在2025年Acr Convergence会议上展示的1期研究数据强调了Kyv-101在类风湿性关节炎中的潜力
美股速递 · 2025-10-25
Kyverna Therapeutics在2025年Acr Convergence会议上展示的1期研究数据强调了Kyv-101在类风湿性关节炎中的潜力
Kyverna Therapeutics, Inc.盘中异动 早盘急速拉升5.48%
市场透视 · 2025-03-05
Kyverna Therapeutics, Inc.盘中异动 早盘急速拉升5.48%
Kyverna Therapeutics, Inc.盘中异动 股价大跌5.28%报2.69美元
市场透视 · 2025-03-03
Kyverna Therapeutics, Inc.盘中异动 股价大跌5.28%报2.69美元
Kyverna Therapeutics, Inc.盘中异动 早盘股价大跌5.17%报2.75美元
市场透视 · 2025-02-26
Kyverna Therapeutics, Inc.盘中异动 早盘股价大跌5.17%报2.75美元
加载更多
公司概况
公司名称：
Kyverna Therapeutics
所属市场：
NASDAQ
上市日期：
--
主营业务：
Kyverna Therapeutics, Inc.于2018年6月14日以BAIT Therapeutics, Inc.的名义在特拉华州注册成立，并于2019年10月更名为Kyverna Therapeutics, Inc.。该公司是一家以患者为中心的临床阶段生物制药公司，专注于为患有自身免疫性疾病的患者开发细胞疗法。该公司的目标是通过以患者为中心的方法、广阔的平台、治疗免疫疾病的洞察力以及细胞疗法在医学领域成功应用的经验教训，为患有自身免疫性疾病的患者带来改变疾病的治疗益处。
发行价格：
--
{"stockData":{"symbol":"KYTX","market":"US","secType":"STK","nameCN":"Kyverna Therapeutics","latestPrice":8.7,"timestamp":1777406400000,"preClose":8.99,"halted":0,"volume":865494,"hourTrading":{"tag":"盘后","latestPrice":8.87,"preClose":8.7,"latestTime":"17:10 EDT","volume":7393,"amount":64355.222198,"timestamp":1777410635113,"change":0.17,"changeRate":0.01954,"amplitude":0.033149},"delay":0,"changeRate":-0.032258064516129135,"floatShares":33297000,"shares":60439900,"eps":-3.644532,"marketStatus":"盘后交易","change":-0.29,"latestTime":"04-28 17:15:25 EDT","open":8.96,"high":9.23,"low":8.58,"amount":7601686.597134,"amplitude":0.072303,"askPrice":8.87,"askSize":100,"bidPrice":8.65,"bidSize":40,"shortable":3,"etf":0,"ttmEps":-3.644532,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1777420800000},"marketStatusCode":4,"adr":0,"listingDate":1707368400000,"exchange":"NASDAQ","adjPreClose":8.99,"preHourTrading":{"tag":"盘前","latestPrice":9.03,"preClose":8.99,"latestTime":"09:28 EDT","volume":4285,"amount":38551.926465000004,"timestamp":1777382928402,"change":0.04,"changeRate":0.004449,"amplitude":0.024472},"postHourTrading":{"tag":"盘后","latestPrice":8.87,"preClose":8.7,"latestTime":"17:10 EDT","volume":7393,"amount":64355.222198,"timestamp":1777410635113,"change":0.17,"changeRate":0.01954,"amplitude":0.033149},"volumeRatio":0.341185,"impliedVol":0.8616,"impliedVolPercentile":0.1235},"requestUrl":"/m/hq/s/KYTX","defaultTab":"news","newsList":[{"id":"1162434050","title":"Kyverna Therapeutics股价大涨7.3% 罕见肌肉疾病细胞疗法中期数据表现强劲","url":"https://stock-news.laohu8.com/highlight/detail?id=1162434050","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1162434050?lang=zh_cn&edition=full","pubTime":"2026-04-22 21:33","pubTimestamp":1776864795,"startTime":"0","endTime":"0","summary":"Kyverna Therapeutics公司股价今日显著上扬，涨幅达7.3%。这一积极市场反应源于该公司针对罕见肌肉疾病的细胞疗法在中期临床试验中取得了令人鼓舞的成果。\n试验数据显示，该疗法在中期阶段展现出强劲的有效性和可控的安全性特征，为后续研发注入了信心。受此利好消息推动，投资者对该公司前景的乐观情绪明显升温，直接反映在股价的强势表现上。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KYTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115847455","title":"Kyverna Therapeutics股价盘前飙升21% 中期试验显示其疗法改善僵人综合征患者活动能力","url":"https://stock-news.laohu8.com/highlight/detail?id=1115847455","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115847455?lang=zh_cn&edition=full","pubTime":"2026-04-22 18:20","pubTimestamp":1776853224,"startTime":"0","endTime":"0","summary":"生物技术公司Kyverna Therapeutics的股价在盘前交易中大幅上涨21%，此前该公司宣布其针对僵人综合征的疗法在中期临床试验中显示出能够显著改善患者的行动能力。\n这一积极数据提振了投资者信心，推动该公司股价在开盘前出现强劲走势。僵人综合征是一种罕见的神经系统疾病，会导致患者肌肉僵硬和痉挛，严重影响日常活动。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113314168","title":"Kyverna Therapeutics公布KYSA-8试验主要分析结果：Miv-Cel治疗SPS取得积极成效","url":"https://stock-news.laohu8.com/highlight/detail?id=1113314168","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1113314168?lang=zh_cn&edition=full","pubTime":"2026-04-22 06:52","pubTimestamp":1776811935,"startTime":"0","endTime":"0","summary":"生物技术公司Kyverna Therapeutics Inc (KYTX) 近日宣布，其针对僵人综合征（SPS）的嵌合抗原受体T细胞疗法Miv-Cel（KYV-101），在名为KYSA-8的临床试验中完成了主要分析。结果显示，该试验达到了预设的主要终点，展现出显著的治疗潜力。\n此次公布的数据进一步验证了Miv-Cel在改善SPS患者临床症状方面的积极效果。公司表示，详细结果将在未来的医学会议上公布，并计划与监管机构讨论后续开发策略。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148269805","title":"Kyverna Therapeutics公布Miv-Cel治疗全身型重症肌无力二期长期积极数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1148269805","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1148269805?lang=zh_cn&edition=full","pubTime":"2026-04-20 20:05","pubTimestamp":1776686742,"startTime":"0","endTime":"0","summary":"生物技术公司Kyverna Therapeutics Inc (KYTX) 近日宣布，其针对全身型重症肌无力的候选疗法Miv-Cel在二期临床试验中取得积极长期随访结果。数据显示，该疗法在延长观察期内持续展现出良好的安全性与耐受性特征，同时关键疗效指标维持稳定改善趋势。这一进展为后续关键临床试验的设计与推进提供了重要依据，也增强了业界对该细胞疗法潜力的信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187806317","title":"Kyverna Therapeutics：24周时100%患者实现MG-ADL与QMG快速持续改善","url":"https://stock-news.laohu8.com/highlight/detail?id=1187806317","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1187806317?lang=zh_cn&edition=full","pubTime":"2026-04-20 20:03","pubTimestamp":1776686634,"startTime":"0","endTime":"0","summary":"临床数据显示，Kyverna Therapeutics在研疗法取得突破性进展——所有受试患者在24周观察期内均展现出肌无力日常生活活动量表和定量肌力测试评分的快速且持久的改善。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126929975","title":"Kyverna Therapeutics与Jefferies签订公开市场销售协议 日期为2025年3月27日——SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1126929975","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126929975?lang=zh_cn&edition=full","pubTime":"2026-04-03 04:51","pubTimestamp":1775163073,"startTime":"0","endTime":"0","summary":"根据一份日期为2025年3月27日提交至美国证券交易委员会的文件显示，Kyverna Therapeutics Inc已与Jefferies LLC正式签署了一项公开市场销售协议。该协议的签订意味着Kyverna Therapeutics已授权Jefferies作为其销售代理，未来可在公开市场上根据市场条件，按公司指示的价格和数量出售其普通股股份。此次协议的签署，反映了Kyverna Therapeutics在资本运作方面的积极布局，旨在为公司的运营和未来发展提供资金支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118984791","title":"Kyverna Therapeutics发布业务进展及2025年第四季度与全年财务业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1118984791","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1118984791?lang=zh_cn&edition=full","pubTime":"2026-03-27 04:03","pubTimestamp":1774555393,"startTime":"0","endTime":"0","summary":"Kyverna Therapeutics（股票代码：KYTX）近日同步披露了公司最新业务动态及2025财年第四季度与全年财务报告。此次公告全面呈现了企业在研发管线推进、战略合作拓展及财务状况方面的关键进展，为投资者评估公司发展轨迹提供了重要依据。通过系统性梳理运营成果与财务数据，Kyverna进一步明确了其在细胞治疗领域的技术布局与商业化路径。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616322697","title":"Kyverna Therapeutics, Inc.盘中异动 快速跳水5.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616322697","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616322697?lang=zh_cn&edition=full","pubTime":"2026-03-03 22:48","pubTimestamp":1772549307,"startTime":"0","endTime":"0","summary":"北京时间2026年03月03日22时48分，Kyverna Therapeutics, Inc.股票出现异动，股价大幅下挫5.29%。截至发稿，该股报8.06美元/股，成交量3.4792万股，换手率0.06%，振幅3.52%。Kyverna Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为1.35%。其相关个股中，Edesa Biotech, Inc.、Calcimedica, Inc.、Hcw Biologics Inc.涨幅较大，Adial Pharmaceuticals, Inc、Propanc Biopharma, Inc.、Edesa Biotech, Inc.较为活跃，换手率分别为116.76%、58.61%、52.81%，振幅较大的相关个股有Edesa Biotech, Inc.、Klotho Neurosciences Inc C/Wts 21/06/2029 、Cardio Diagnostics Holdings Inc.，振幅分别为40.79%、27.40%、23.03%。Kyverna Therapeutics, Inc.公司简介：Kyverna Therapeutics Inc是一家临床阶段生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026030322482797a7e086&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026030322482797a7e086&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","KYTX","BK4007","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2607083052","title":"Kyverna Therapeutics, Inc.盘中异动 股价大跌5.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2607083052","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607083052?lang=zh_cn&edition=full","pubTime":"2026-01-28 22:50","pubTimestamp":1769611836,"startTime":"0","endTime":"0","summary":"北京时间2026年01月28日22时50分，Kyverna Therapeutics, Inc.股票出现异动，股价大幅下跌5.06%。Kyverna Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.78%。其相关个股中，Liminatus Pharma Inc C/Wts 30/04/2030 、Revolution Medicines Inc C/Wts 17/12/2026 、Nextcure, Inc.涨幅较大，Gri Bio, Inc.、60 Degrees Pharmaceuticals, Inc.、Calcimedica, Inc.较为活跃，换手率分别为1957.74%、116.29%、90.54%，振幅较大的相关个股有Jasper Therapeutics Inc C/Wts 24/09/2026 、Gri Bio, Inc.、Briacell Therapeutics Corp C/Wts ，振幅分别为85.71%、27.44%、25.75%。Kyverna Therapeutics, Inc.公司简介：Kyverna Therapeutics Inc是一家临床阶段生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260128225037a460de6c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260128225037a460de6c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","KYTX","BK4539","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2602720983","title":"Kyverna Therapeutics, Inc.盘中异动 下午盘快速跳水5.06%报8.26美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2602720983","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602720983?lang=zh_cn&edition=full","pubTime":"2026-01-09 04:02","pubTimestamp":1767902551,"startTime":"0","endTime":"0","summary":"北京时间2026年01月09日04时02分，Kyverna Therapeutics, Inc.股票出现波动，股价大幅跳水5.06%。截至发稿，该股报8.26美元/股，成交量57.6845万股，换手率0.97%，振幅6.76%。Kyverna Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为2.32%。其相关个股中，Enliven Therapeutics, Inc.、Century Therapeutics, Inc.、Moonlake Immunotherapeutics涨幅较大，Pmgc Holdings Inc.、Acrivon Therapeutics, Inc.、Gri Bio, Inc.较为活跃，换手率分别为527.89%、127.75%、81.83%，振幅较大的相关个股有Abpro Holdings Inc C/Wts 12/11/2029 、Enliven Therapeutics, Inc.、Briacell Therapeutics Corp C/Wts 26/02/2026，振幅分别为146.48%、59.43%、52.53%。Kyverna Therapeutics, Inc.公司简介：Kyverna Therapeutics Inc是一家临床阶段生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260109040232953c3d0e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260109040232953c3d0e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4539","KYTX","LENZ","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124946336","title":"新闻稿：Kyverna Therapeutics宣布拟进行普通股的公开发行","url":"https://stock-news.laohu8.com/highlight/detail?id=1124946336","media":"投资观察","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1124946336?lang=zh_cn&edition=full","pubTime":"2025-12-16 05:03","pubTimestamp":1765832595,"startTime":"0","endTime":"0","summary":"加利福尼亚州阿梅里维尔，2025年12月15日-- Kyverna Therapeutics, Inc.是一家专注于为自身免疫疾病患者开发细胞疗法的临床阶段生物制药公司，今天宣布已启动一项1亿美元的普通股承销公开发行。Kyverna打算给予承销商一个30天的选择权，以按照公开发行价格、扣除承销折扣和佣金的条件，额外购买最多1500万美元的普通股。所有将在拟议发行中出售的普通股均由Kyverna出售。J.P. Morgan、Leerink Partners、Morgan Stanley和Wells Fargo Securities作为该发行的联合簿记管理人。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","LU0098860793.USD","LU0795875086.SGD","BK4516","LU1989772923.USD","BK4504","LU0234570918.USD","LU0882574139.USD","BK4534","LU1720051108.HKD","LU2271345857.HKD","LU0267386448.USD","LU0106261372.USD","LU1074936037.SGD","LU0971096721.USD","BK4139","LU0795875169.SGD","MS","LU1791710582.SGD","LU2089284900.SGD","LU1244550577.SGD","LU2347655156.SGD","LU1548497426.USD","IE00BZ1G4Q59.USD","LU0106831901.USD","LU0158827948.USD","KYTX","LU0528227936.USD","LU1244550494.USD","LU0557290698.USD","LU2357305700.SGD","LU1244550221.USD","BK4585","IE00BKVL7J92.USD","LU0225283273.USD","LU2089283258.USD","BK4581","LU1162221912.USD","LU1732800096.USD","LU1720051017.SGD","LU1989772840.SGD","LU0006306889.USD","LU2133065610.SGD","BK4588","LU0158827781.USD","LU2028103732.USD","LU1732799900.SGD","LU0912757837.SGD","LU1363072403.SGD","LU1668664300.SGD","LU0320765646.SGD","LU2023251221.USD","BK4127","LU1791710400.SGD","LU2111349929.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196824119","title":"Kyverna Therapeutics公布Miv-Cel (Kyv-101)在僵人综合征注册Kysa-8试验中的积极关键数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1196824119","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1196824119?lang=zh_cn&edition=full","pubTime":"2025-12-15 19:30","pubTimestamp":1765798215,"startTime":"0","endTime":"0","summary":"Kyverna Therapeutics公布Miv-Cel (Kyv-101)在僵人综合征注册Kysa-8试验中的积极关键数据","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KYTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170285047","title":"Kyverna Therapeutics将发布Kyv-101在僵人综合症注册性第二阶段Kysa-8试验的顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1170285047","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1170285047?lang=zh_cn&edition=full","pubTime":"2025-12-15 03:31","pubTimestamp":1765740676,"startTime":"0","endTime":"0","summary":"Kyverna Therapeutics将发布Kyv-101在僵人综合症注册性第二阶段Kysa-8试验的顶线结果","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2581779056","title":"Caribou Biosciences报告了关于同种异体CAR T疗法的临床数据，而Kyverna Therapeutics则推进了自身免疫项目Caribou Biosciences Reports Clinical Data on Allogeneic CAR T Therapies While Kyverna Therapeutics Advances Autoimmune Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2581779056","media":"动脉网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581779056?lang=zh_cn&edition=full","pubTime":"2025-11-05 16:03","pubTimestamp":1762329780,"startTime":"0","endTime":"0","summary":"Caribou presented findings from trials involving its allogeneic CAR T therapies, which use donor-derived cells rather than a patient’s own cells. These therapies were tested in two separate cancer indications, though specific details regarding efficacy or safety outcomes were not disclosed in the report.Caribou公布了其同种异体CAR T疗法的试验结果，该疗法使用捐赠者来源的细胞而非患者自身的细胞。Meanwhile, Kyverna announced plans to move forward with its CAR T program aimed at treating autoimmune conditions. This marks a shift from the traditional focus of CAR T therapy on oncology and represents an effort to expand the technology’s applications into other therapeutic areas. Both companies continue to explore innovative approaches within this rapidly evolving sector of biotechnology..同时，Kyverna 宣布计划推进其旨在治疗自身免疫性疾病的 CAR T 项目。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025110516052697554e2c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025110516052697554e2c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4022","CRBU","KYTX","BK4007","BK4230","LENZ","BK4139","BK4539","CAR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180745023","title":"Kyverna Therapeutics公司预计现金流可持续至2027年，支持其SPS的BLA申请及Mg三期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1180745023","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1180745023?lang=zh_cn&edition=full","pubTime":"2025-11-03 21:04","pubTimestamp":1762175058,"startTime":"0","endTime":"0","summary":"Kyverna Therapeutics公司预计现金流可持续至2027年，支持其SPS的BLA申请及Mg三期临床试验。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166583441","title":"Kyverna Therapeutics公布Kysa-6研究中Kyv-101在广泛性重症肌无力治疗中的积极一期2临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1166583441","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1166583441?lang=zh_cn&edition=full","pubTime":"2025-10-29 18:31","pubTimestamp":1761733875,"startTime":"0","endTime":"0","summary":"Kyverna Therapeutics公布了Kysa-6研究中Kyv-101在广泛性重症肌无力治疗中的积极一期2临床数据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104181247","title":"Kyverna Therapeutics在2025年Acr Convergence会议上展示的1期研究数据强调了Kyv-101在类风湿性关节炎中的潜力","url":"https://stock-news.laohu8.com/highlight/detail?id=1104181247","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1104181247?lang=zh_cn&edition=full","pubTime":"2025-10-25 23:00","pubTimestamp":1761404411,"startTime":"0","endTime":"0","summary":"Kyverna Therapeutics在2025年Acr Convergence会议上展示的1期研究数据强调了Kyv-101在类风湿性关节炎中的潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517394880","title":"Kyverna Therapeutics, Inc.盘中异动 早盘急速拉升5.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517394880","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517394880?lang=zh_cn&edition=full","pubTime":"2025-03-05 22:41","pubTimestamp":1741185660,"startTime":"0","endTime":"0","summary":"北京时间2025年03月05日22时41分，Kyverna Therapeutics, Inc.股票出现异动，股价急速拉升5.48%。Kyverna Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.68%。其相关个股中，Chimerix, Inc.、Klotho Neurosciences Inc C/Wts 21/06/2029 、Celularity Inc C/Wts 16/07/2026 涨幅较大，Silexion Therapeutics Corp、Tc Biopharm Plc、Bioxcel Therapeutics, Inc.较为活跃，换手率分别为414.92%、265.37%、199.22%，振幅较大的相关个股有Aditxt, Inc.、Silexion Therapeutics Corp、Tonix Pharmaceuticals Holding Corp.，振幅分别为23.90%、20.71%、19.74%。Kyverna Therapeutics, Inc.公司简介：Kyverna Therapeutics Inc 是一家临床阶段生物制药公司。其产品KYV-101是一种自体 CD19 CAR T细胞候选产品，由潜在的嵌合抗原受体制成。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305224100a260cad8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305224100a260cad8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["KYTX","BK4139","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516663055","title":"Kyverna Therapeutics, Inc.盘中异动 股价大跌5.28%报2.69美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516663055","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516663055?lang=zh_cn&edition=full","pubTime":"2025-03-03 23:06","pubTimestamp":1741014392,"startTime":"0","endTime":"0","summary":"北京时间2025年03月03日23时06分，Kyverna Therapeutics, Inc.股票出现波动，股价快速跳水5.28%。截至发稿，该股报2.69美元/股，成交量4.8885万股，换手率0.11%，振幅7.04%。Kyverna Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.12%。其相关个股中，Bioxcel Therapeutics, Inc.、Estrella Immunopharma Inc C/Wts 29/09/2028、Entero Therapeutics Inc.涨幅较大，Bioxcel Therapeutics, Inc.、Entero Therapeutics Inc.、Allarity Therapeutics, Inc.较为活跃，换手率分别为1138.48%、126.15%、102.55%，振幅较大的相关个股有Bioxcel Therapeutics, Inc.、Entero Therapeutics Inc.、Pliant Therapeutics, Inc.，振幅分别为163.15%、70.53%、48.34%。Kyverna Therapeutics, Inc.公司简介：Kyverna Therapeutics Inc 是一家临床阶段生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303230632a25d4abf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303230632a25d4abf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","KYTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514763011","title":"Kyverna Therapeutics, Inc.盘中异动 早盘股价大跌5.17%报2.75美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514763011","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514763011?lang=zh_cn&edition=full","pubTime":"2025-02-26 00:29","pubTimestamp":1740500969,"startTime":"0","endTime":"0","summary":"北京时间2025年02月26日00时29分，Kyverna Therapeutics, Inc.股票出现波动，股价急速跳水5.17%。Kyverna Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.34%。其相关个股中，Abpro Holdings Inc C/Wts 12/11/2029 、Silexion Therapeutics Corp、Conduit Pharmaceuticals Inc C/Wts 22/09/2028涨幅较大，Gt Biopharma, Inc.、Silexion Therapeutics Corp、Moleculin Biotech, Inc.较为活跃，换手率分别为1115.47%、909.65%、660.96%，振幅较大的相关个股有Silexion Therapeutics Corp、Abpro Holdings Inc C/Wts 12/11/2029 、Adial Pharmaceuticals, Inc，振幅分别为87.83%、66.67%、64.05%。Kyverna Therapeutics, Inc.公司简介：Kyverna Therapeutics Inc 是一家临床阶段生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022600293096300be9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022600293096300be9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["KYTX","LENZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://kyvernatx.com","stockEarnings":[{"period":"1week","weight":-0.2009},{"period":"1month","weight":0.1526},{"period":"3month","weight":-0.0312},{"period":"6month","weight":0.2538},{"period":"1year","weight":3.281},{"period":"ytd","weight":-0.0436}],"compareEarnings":[{"period":"1week","weight":0.0091},{"period":"1month","weight":0.1279},{"period":"3month","weight":0.0283},{"period":"6month","weight":0.0404},{"period":"1year","weight":0.2988},{"period":"ytd","weight":0.0488}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Kyverna Therapeutics, Inc.于2018年6月14日以BAIT Therapeutics, Inc.的名义在特拉华州注册成立，并于2019年10月更名为Kyverna Therapeutics, Inc.。该公司是一家以患者为中心的临床阶段生物制药公司，专注于为患有自身免疫性疾病的患者开发细胞疗法。该公司的目标是通过以患者为中心的方法、广阔的平台、治疗免疫疾病的洞察力以及细胞疗法在医学领域成功应用的经验教训，为患有自身免疫性疾病的患者带来改变疾病的治疗益处。","exchange":"NASDAQ","name":"Kyverna Therapeutics","nameEN":"Kyverna Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Kyverna Therapeutics(KYTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Kyverna Therapeutics(KYTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Kyverna Therapeutics,KYTX,Kyverna Therapeutics股票,Kyverna Therapeutics股票老虎,Kyverna Therapeutics股票老虎国际,Kyverna Therapeutics行情,Kyverna Therapeutics股票行情,Kyverna Therapeutics股价,Kyverna Therapeutics股市,Kyverna Therapeutics股票价格,Kyverna Therapeutics股票交易,Kyverna Therapeutics股票购买,Kyverna Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Kyverna Therapeutics(KYTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Kyverna Therapeutics(KYTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}